[…] Engagement “Positive benefit/risk supports losmapimod’s potential to be a transformative therapy for the treatment of FSHD”-Fulcrum Therapeutics Fulcrum Therapeutics announced today that losmapimod, its experimental therapy for facioscapulohumeral muscular dystrophy, […]
ReDUX4 trial result exceeds expectations
Tampa Chapter
Welcome to the Tampa Chapter! Thank you for visiting the Tampa Chapter of the FSHD Society which officially launched in May 2019. We are here to build a local community […]
First patient enrolls in Fulcrum’s Phase 3 clinical trial
Losmapimod has the potential to be the first drug to treat FSHD The much-anticipated Phase 3 clinical trial of losmapimod has formally begun with the dosing of the first volunteer, […]
$3.4 million to speed us along our journey (Part 1)
[…] funded will help us get more and better treatments to our community by June Kinoshita, FSHD Society Many of you have heard us describe the FSHD Society as a “research-focused […]
Gene Interference Technology Used Against FSH Muscular Dystrophy Genetic Defect
[…] the award-winning non-profit and global leader in the quest to cure Facioscapulohumeral Muscular Dystrophy ( FSHD), announced that an FSH Society-funded research team led by Peter Jones, PhD, at the […]